Immunotherapy for cervical cancer - can it do another lung cancer?

Publication date: Available online 6 January 2018
Source:Current Problems in Cancer
Author(s): Ramanathan Priya, Dhandapani Hemavathi, Jayakumar Hascitha, Seetharaman Abirami, Thangarajan Rajkumar
Cervical cancer, although preventable, is still the second most common cancer among women worldwide. In developing countries like India, where screening for cervical cancer is virtually absent, most women seek treatment only at advanced stages of the disease. Although standard treatment is curative in more than 90% of women during the early stages, for Stage IIIb and above this rate drops to 50% or less. Hence, novel therapeutic adjuvants are required to improve survival at advanced stages. Lung cancer has shown the way forward with the use of Immunotherapeutic interventions as standard line of treatment in advanced stages. In this review, we provide an overview of mechanisms of immune evasion, strategies that can be employed to boost the immune system in order to improve the overall survival of the patients and summarize briefly the clinical trials that have been completed or that are underway to bring therapeutic vaccines for cervical cancer to the clinics.



http://ift.tt/2CNZvFr